Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.22
  • Today's Change-5.07 / -18.58%
  • Shares traded4.31m
  • 1 Year change-21.04%
  • Beta1.4012
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments15,32616,93713,582
Total Receivables, Net9,6979,1358,037
Total Inventory7,5386,8825,472
Prepaid expenses9091,6321,757
Other current assets, total3226931,576
Total current assets33,79335,27930,425
Property, plant & equipment, net23,67117,39514,445
Goodwill, net10,85210,3379,400
Intangibles, net17,37815,92513,433
Long term investments25,01225,54923,920
Note receivable - long term28221377
Other long term assets96484180
Total assets113,470107,16493,294
LIABILITIES
Accounts payable5,5075,4264,515
Accrued expenses2,3321,8851,511
Notes payable/short-term debt15,83613,27411,747
Current portion long-term debt/capital leases4,7525,4145,127
Other current liabilities, total5,3307,2996,408
Total current liabilities33,75833,29829,310
Total long term debt15,89113,0379,905
Total debt36,47931,72526,780
Deferred income tax3,4453,3633,130
Minority interest10,9319,5269,184
Other liabilities, total3,7603,3572,574
Total liabilities67,78562,58154,102
SHAREHOLDERS EQUITY
Common stock2,6722,6722,563
Additional paid-in capital16,85316,99214,029
Retained earnings (accumulated deficit)27,50126,17023,866
Treasury stock - common(42)(53)--
Unrealized gain (loss)(237)(19)114
Other equity, total(1063)(1180)(1380)
Total equity45,68544,58239,192
Total liabilities & shareholders' equity113,470107,16493,294
Total common shares outstanding2,6702,6702,563
Treasury shares - common primary issue1.972.500
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.